4198.Two
4198.TWO operates in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.
Business. 4198.TWO operates in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
4198.TWO operates in the Advanced Medical Equipment & Technology industry, specializing in the development and provision of medical equipment and technology solutions.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.13, indicating a conservative approach to leverage. With cash and equivalents amounting to 106,846,000 TWD, the company maintains a strong liquidity position, as reflected in a current ratio of 2.93. However, the company reported negative operating and net income, with operating income at -46,569,000 TWD and net income at -47,295,000 TWD, suggesting a lack of profitability. The return on equity and return on assets are also negative, at -20.88% and -12.54%, respectively, indicating poor returns on invested capital.
The company's profitability is below the industry median, as evidenced by the negative operating and net income figures. The negative returns on equity and assets further underscore the company's underperformance in generating returns for shareholders and utilizing assets efficiently. The company's operating cash flow is also negative at -26,657,000 TWD, which may indicate challenges in generating sufficient cash from operations to sustain its activities.
The company's revenue is concentrated in a single segment, as no segmental breakdown is provided in the available data. The geographic exposure is not specified, but the company's operations are likely centered in the region where it is listed. The lack of segmental and geographic diversification may pose a concentration risk, as the company's performance is tied to a single market or product line.
The company's growth trajectory is uncertain, as the most recent revenue figure is 204,212,000 TWD, and there is no indication of a clear growth path in the near term. The negative operating and net income figures suggest that the company may need to address its cost structure or revenue generation strategies to achieve profitability. The company's capital expenditure of -3,522,000 TWD indicates a reduction in investment in long-term assets, which may affect its ability to grow and innovate.
The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's free cash flow is negative at -31,913,000 TWD, which may limit its ability to fund operations and investments without external financing. The dilution potential is low, as the number of shares outstanding for both basic and diluted shares is the same, indicating no imminent threat of share dilution.
Recent events related to the company include the latest actual revenue of 463,700,000 TWD, as reported by analyst estimates. This figure is significantly higher than the most recent reported revenue, suggesting a potential discrepancy or a need for further investigation into the company's financial reporting.
- The company has a strong liquidity position with a current ratio of 2.93 and significant cash and equivalents.
- The company is not profitable, with negative operating and net income figures.
- The company's return on equity and return on assets are negative, indicating poor returns on invested capital.
- The company's growth trajectory is uncertain, with no clear path to profitability.
- The company's risk profile is low in terms of liquidity and dilution, but its financial performance is a concern.
- "margin_outlook_rationale": "The company's margin outlook is negative due to the reported negative operating and net income figures.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4198.TWO Market data — financials · 2026-05-26
- S&S Healthcare Holding Ltd Market data — analyst estimates · 2026-05-26